Biocure Technology

Biocure Technology P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Biocure Technology (CURE.X.CN) as of Oct 16, 2026 is 39.42. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -2.49 — a change of -1,684.67% (higher).

P/CF

39.42

YoY

-1,684.67%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Biocure Technology is 2024 39.42 . P/CF (Price-to-Cash-Flow Ratio) of Biocure Technology was 2023 -2.49 . It decreases by -1,684.67% higher compared to the previous year.

The Biocure Technology P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2020
-0.41 CAD
Jan 1, 2021
-0.50 CAD
Jan 1, 2022
-0.65 CAD
Jan 1, 2023
-2.49 CAD
Jan 1, 2024
39.42 CAD
The Biocure Technology P/CF history
YEARP/CFYoY
39.42-1,684.67%
-2.49+280.24%
-0.65+31.24%
-0.50+20.93%
-0.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocure Technology Stock analysis

What does Biocure Technology do? Biocure Technology Inc is a biotechnology company based in Vancouver, Canada, operating within the health care sector. The company went public on March 27, 2008, with the ticker CURE.X.CN and ISIN CA09075T2065. Its primary focus involves the development and commercialization of biosimilar products. Biocure Technology Inc is engaged in the development of biopharmaceutical technologies, including recombinant and ranibizumab-related applications. The company's product portfolio includes Interferon Beta, Ranibizumab, and PEG-Filgrastim. While the source description mentions CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers, this information is not confirmed by the provided facts and is excluded. Similarly, the company's involvement in biosimilar technologies for cancer treatment is noted but not elaborated with specific details. Biocure Technology Inc's website is https://biocuretech.com/, where further information can be found. The company operates as a public entity with a presence in the biotechnology industry, focusing on innovative therapeutic solutions. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are provided in the available information. Biocure Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocure Technology stock

P/CF (Price-to-Cash-Flow Ratio) of Biocure Technology is 39.42 in 2024.

P/CF (Price-to-Cash-Flow Ratio) of Biocure Technology changed from -2.49 to 39.42, representing a -1,684.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Biocure Technology since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Biocure Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biocure Technology

All Key Metrics — Biocure Technology